Pancreatic ductal adenocarcinoma: Current and evolving therapies

QR Code

Pancreatic ductal adenocarcinoma: Current and evolving therapies

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of...

Full description

Bibliographic Details
Main Authors:	Adamska, A., Domenichini, A., Falasca, Marco
Format:	Journal Article
Published:	MDPI AG 2017
Online Access:	http://hdl.handle.net/20.500.11937/54405

Similar Items

CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
by: Amin-Tai, Hizami, et al.
Published: (2023)

ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
by: Adamska, A., et al.
Published: (2018)

The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays
by: Tewari, Nilanjana, et al.
Published: (2013)

Total pancreatectomy for diffuse pancreatic adenocarcinoma
by: Azlanudin A,, et al.
Published: (2011)

ABC transporters as cancer drivers: Potential functions in cancer development
by: Domenichini, Alice, et al.
Published: (2019)

Pancreatic cancer: Current research and future directions
by: Falasca, Marco, et al.
Published: (2016)

Diet and pancreatic cancer prevention
by: Casari, I., et al.
Published: (2015)

Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
by: Adamska, Aleksandra, et al.
Published: (2018)

Emerging role of the KRAS-PDK1 axis in pancreatic cancer
by: Ferro, R., et al.
Published: (2014)

Investigating the mechanisms of activation and action of phosphoinositide 3-kinase C2 alpha in pancreatic beta cells
by: Mazza, S., et al.
Published: (2013)

Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
by: Elaskalani, O., et al.
Published: (2017)

Phenotypic and molecular characterisation of breast ductal carcinoma in situ
by: Abdelaziz, Islam Mohammed Samy Miligy
Published: (2019)

Pancreatic cancer treatment with targeted therapies: are we there yet
by: Nwaefulu, O. Ngozi, et al.
Published: (2022)

Targeting phosphoinositide 3-kinase pathways in pancreatic cancer - from molecular signalling to clinical trials
by: Falasca, Marco, et al.
Published: (2011)

Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
by: Butler-Henderson, Kerryn Ann
Published: (2014)

Identification Of Biomarkers In Infiltrating Ductal Carcinoma: A Proteomics Approach
by: Seng , Liang
Published: (2009)

Bcl-2 expression and clinico-pathological correlations in invasive ductal carcinoma of the breast
by: Al-Joudi, Fawwaz S.,, et al.
Published: (2010)

The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance
by: Elaskalani, Omar, et al.
Published: (2017)

Serum leptin might be causally correlated to invasive ductal breast carcinoma
by: Al-Shibli, Saad M., et al.
Published: (2018)

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast
by: Toss, Michael S., et al.
Published: (2018)

Exploring the role of tumour microenvironment in the behaviour of breast ductal carcinoma in situ
by: Toss, Michael Salah Shawky
Published: (2020)

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
by: Ferro, R., et al.
Published: (2018)

Pancreatic cystosis: A rare pancreatic manifestation in cystic fibrosis
by: Mohammad A. Wazzan,
Published: (2015)

Key role of phosphoinositide 3-kinase class IB in pancreatic cancer
by: Edling, C., et al.
Published: (2010)

The leptin transduction pathway may be targeted against invasive ductal carcinoma of breast
by: M.Rahman, Shaikh, et al.
Published: (2018)

Epidemiology of Ductal Carcinoma in Situ in Western Australia: Implications for Surgical Margins and Management
by: Butler-Henderson, Kerryn, et al.
Published: (2014)

Performance of linear and stochastic cell-growth model of Ductal Carcinoma In Situ (DCIS)
by: Nurul Anis, Abdul Satar, et al.
Published: (2025)

Breast invasive ductal carcinoma detection with histopathological images using deep learning
by: Voon, Wingates
Published: (2022)

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
by: Ferro, Riccardo, et al.
Published: (2018)

Thioredoxin interacting protein (TXNIP) is an independent risk stratifier for breast ductal carcinoma in situ
by: Miligy, Islam, et al.
Published: (2018)

Hypermutation In Pancreatic Cancer
by: Humphris, J., et al.
Published: (2017)

Evolving Malaysia
by: Ani, Mohd Hanafi
Published: (2009)

Pancreatic injuries
by: Hassan, Radhiana
Published: (2018)

CNN-based deep learning approach for classification of invasive ductal and metastasis types of breast carcinoma
by: Islam, Md. Tobibul, et al.
Published: (2024)

Human pancreatic islet transplantation: an update and description of the establishment of a pancreatic islet isolation laboratory
by: Rheinheimer, J., et al.
Published: (2015)

Class II Phosphoinositide 3-Kinases as Novel Drug Targets
by: Falasca, Marco, et al.
Published: (2017)

Medicine an evolving profession
by: Jiwa, Moyez
Published: (2013)

Evolving character animation
by: Zakaria, M. Nordin
Published: (2001)

Evolve or lose competitiveness
by: Ong, Tze San, et al.
Published: (2021)

Exclusive intronic p53 point mutations detected in heterozygous invasive ductal breast carcinoma samples
by: Rosli, Rozita, et al.
Published: (2002)

Cannot write session to /tmp/vufind_sessions/sess_33bc6d1adnd4l9d0jj6eq1toco